Abstract: The present invention describes a low-cost apparatus for selectively brewing stronger coffee. The invention provides for a switch and two circuits integral to the coffee maker whereby the user can manually select between a regular brew and a strong brew accomplished by adding in a second circuit.

Abstract: An embodiment of a semiconductor package apparatus may include technology to determine one or more conditions for a set of primitives, and perform primitive replication at a vertex shader based on the determined one or more conditions for the set of primitives. Other embodiments are disclosed and claimed.

Abstract: An embodiment of a semiconductor package apparatus may include technology to determine one or more conditions for a set of primitives, and perform primitive replication at a vertex shader based on the determined one or more conditions for the set of primitives. Other embodiments are disclosed and claimed.

Abstract: The invention disclosed herein is directed to a smart slow cooker, system, and related methods for heating food to at least 50 degrees centigrade within at most two hours, then adjusting the power to a lower setting for the remainder of the desired cooking time.

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: Method of making foamed gypsum slurry having 15 to 90 volume percent gas bubbles including: passing first slurry including water and on dry basis 50 to 98 wt. % calcium sulfate hemihydrate, 1 to 50 wt. % calcium carbonate, and 0.1 to 10 wt. % cellulose thickener via a first hose to a Wye connector conduit first inlet opening at Rate C and passing alum solution via a second hose to a second inlet opening of the conduit at Rate D to create combined mixed stream passing from the conduit to a static mixer for mixing for Time 3 to activate at least a portion of the calcium carbonate and alum to generate CO2 and create the foamed gypsum slurry; transferring the slurry from the mixer to a cavity between two wall boards via a third hose. Allowing the slurry in the cavity to expand, harden and dry.

Abstract: This disclosure provides methods and compositions for genetically manipulating genes and cells.

Abstract: An apparatus to facilitate pixel compression is disclosed. The apparatus includes a rasterizer module to convert an image to a plurality of pixels, an interface coupled to the rasterizer module, a depth check module coupled to the interface and compression logic to perform a compression encoding on the plurality of pixels, including dividing the plurality of pixels into a mega pixel block having a plurality of pixel blocks, determining coverage information for pixels in each of the plurality of pixel blocks, encoding each of the plurality of pixel blocks based on the coverage information to generate a mega encoded block.

Abstract: A Spontaneous Area Network (SPAN) is formed by mobile and fixed nodes using wireless transmission links between nodes, usually in a nearby geographical area. Applications allow users to create, join, leave, and manage SPANs and groups in a SPAN. Automatic procedures allow nodes to join other SPANs. Transmission power of the wireless network interface is dynamic, varying depending on battery level, type of information to transmit, state and topology of the network. A delay tolerant object layer abstraction creates, modifies, deletes, publishes, and handles Delay Tolerant Distributed Objects (DTDOs). A Patient Transport Protocol (PTP) ensures a reliable transport of information through the network while avoiding congestion conditions. An aggressive and explosive network protocol (AGENET) has routing and forwarding capacities and uses datagrams to establish communication between different nodes of the SPAN.

Abstract: A medical system is provided. The medical system includes a guidewire configured to guide a catheter to a target location within a body, the guidewire including a sensor configured to collect sensor data indicative of a location within the body, and an electrical conductor configured to conduct electrical signals representing the sensor data. The medical system further includes a wireless transmitter and a first antenna electrically coupled with the sensor via the electrical conductor and configured to: receive the electrical signals representing the sensor data; generate, from the electrical signals, first wireless signals representing the sensor data; and transmit, via the first antenna, first wireless signals.

Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: The present invention relates to compounds of formula I: in which X1, X2, X3, Y1, Y2, Y3, R1, R2, R3a, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: Polymerization processes comprising melt polymerizing a carbonate and a dihydroxy compound in the presence of an amount of a beta organic catalyst so as to give rise to a polycarbonate product, wherein the amount of beta organic catalyst comprises at least one onium salt and also comprises triphenyl phosphonium oxide (TPPO), and wherein the TPPO represents less than about 0.3 weight % of the sum of the weights of the at least one onium salt and the TPPO in the amount of beta organic catalyst.

Abstract: An apparatus to facilitate pixel compression is disclosed. The apparatus includes a rasterizer module to convert an image to a plurality of pixels, an interface coupled to the rasterizer module, a depth check module coupled to the interface and compression logic to perform a compression encoding on the plurality of pixels, including dividing the plurality of pixels into a mega pixel block having a plurality of pixel blocks, determining coverage information for pixels in each of the plurality of pixel blocks, encoding each of the plurality of pixel blocks based on the coverage information to generate a mega encoded block.

Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.